Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA Psychiatry, researchers report that semaglutide, better known as Ozempic or Wegovy, helped people with alcohol addiction reduce their craving and drink less.

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

A new study has raised serious concerns about Ozempic, the weight-loss drug taking the world by storm. While it has reportedly helped many people manage their weight and regulate blood sugar, recent research has uncovered an alarming and unexpected side effect: vision loss.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.

Health experts are investigating a possible link between popular weight loss drugs like Ozempic and sudden blindness.

Anne-Marie Zanzal, 60, and her wife Tonda McKay, 62, have also experienced the more positive changes that weight-loss drugs can have on romantic relationships. They say they had reached the "fat and happy stage of life" but realized being overweight was affecting their energy levels.

Millions of Americans use GLP-1 injections like Ozempic to lose weight. A study is questioning whether they can cause vision loss.